Recent Updates
Recently added Catalysts
CON Positive Sentiment

Concentra Appoints Tanner Newton Chief Financial Officer

Tuesday, September 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Concentra has appointed Tanner Newton as its new Chief Financial Officer, effective November 1, 2026. Newton, currently the senior vice president of strategy and finance, will report to Matt DiCanio, who is transitioning to president and CEO on the same date. This leadership change is part of Concentra's strategy for continued growth in occupational medicine.

Market Sentiment Analysis

POSITIVE FACTORS

  • Tanner Newton's appointment signals strong leadership continuity.
  • Concentra is positioning itself for future growth with strategic leadership.
  • The transition in leadership is planned for a specific future date, ensuring stability.

Full Press Release Details

DALLAS--(BUSINESS WIRE)--Concentra® (NYSE: CON), the nation’s leader in occupational medicine and workforce health services, today announced that Tanner Newton, senior vice president of strategy and finance, has been appointed executive vice president and chief financial officer, effective Nov. 1, 2026. Newton will continue to report to Matt DiCanio, Concentra’s president and chief financial officer, who will become president and chief executive officer on Nov. 1, 2026. Newton will lead Concent

Frequently Asked Questions

Who is the new CFO of Concentra?

Tanner Newton has been appointed as the new Chief Financial Officer.

When will Tanner Newton assume the CFO role?

He will take on the role effective November 1, 2026.

Who will Tanner Newton report to?

He will report to Matt DiCanio, who will become CEO on the same date.

What is Tanner Newton's current position?

He is currently the senior vice president of strategy and finance.

ShareAdd on Google
Tags: CON Viatris Investor Conferences Healthcare Concentra Tanner Newton CFO appointment occupational medicine leadership change
Last updated: Sep 8, 2026

Biotech snapshot

Cash runway
$158M liquidity · $0M/mo burn
Low dilution risk